Novartis AG ADR (NVS)vsPTC Therapeutics Inc (PTCT)
NVS
Novartis AG ADR
$137.16
+1.36%
HEALTHCARE · Cap: $260.70B
PTCT
PTC Therapeutics Inc
$66.06
-1.94%
HEALTHCARE · Cap: $5.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 5520% more annual revenue ($56.69B vs $1.01B). NVS leads profitability with a 22.5% profit margin vs -3.8%. PTCT appears more attractively valued with a PEG of 0.81. PTCT earns a higher WallStSmart Score of 52/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PTCT
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for PTCT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Strong operational efficiency at 41.3%
Revenue surging 101.5% year-over-year
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
ROE of -7740.0% — below average capital efficiency
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : PTCT
The strongest argument for PTCT centers on Operating Margin, Revenue Growth, Debt/Equity. Revenue growth of 101.5% demonstrates continued momentum. PEG of 0.81 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PTCT
The primary concerns for PTCT are EPS Growth, Return on Equity, Altman Z-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while PTCT is a hypergrowth play — different risk/reward profiles.
PTCT carries more volatility with a beta of 0.55 — expect wider price swings.
PTCT is growing revenue faster at 101.5% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
PTCT scores higher overall (52/100 vs 51/100) and 101.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →PTC Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is headquartered in South Plainfield, New Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?